+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Surfactant-associated proteins in tracheal aspirates of infants with respiratory distress syndrome after surfactant therapy



Surfactant-associated proteins in tracheal aspirates of infants with respiratory distress syndrome after surfactant therapy



American Review of Respiratory Disease 137(4): 943-947



We have developed enzyme-linked immunoassays (ELISAs) that measure major proteins that are associated with pulmonary surfactant. Using these ELISAs, we tested sequential tracheal aspirates from infants severely ill with respiratory distress syndrome (RDS) who had been treated either with exogenous surfactant or with placebo within 8 h of birth. On average, we found low concentrations of surfactant proteins in tracheal aspirates on Day 1 of life, with increases evident by Day 3. The surfactant used in this study (TA surfactant) contains only the low molecular weight (6 kDa) surfactant proteins and not the 35 kDa surfactant protein. As we expected, those who were treated with TA surfactant more frequently had detectable concentrations of low molecular weight surfactant protein on the second day of life when compared with control infants. No differences were evident in the concentrations of surfactant proteins between the 2 groups by Day 3, nor were differences evident between the 2 groups evident for 35 kDa surfactant protein during the first 3 days of life. Increased low molecular weight surfactant proteins in tracheal aspirates 1 to 2 days after surfactant therapy may occur either because of persistence of exogenous surfactant proteins and/or enhanced surfactant protein production. Comparisons with measurements from other groups of patients with RDS confirm that absence of both surfactant proteins reflects alveolar surfactant deficiency.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 041495178

Download citation: RISBibTeXText

PMID: 3355003

DOI: 10.1164/ajrccm/137.4.943


Related references

Surfactant proteins and stable microbubbles in tracheal aspirates of infants with respiratory distress syndrome: Relation to the degree of respiratory failure and response to exogenous surfactant. European Journal of Pediatrics 156(2): 131-138, 1997

Surfactant proteins in tracheal aspirates after surfactant treatment of respiratory distress syndrome. Pediatric Research 20(4 Part 2): 425A, 1986

Surfactant therapy modulates levels of interleukin-6 and interleukin-1B in tracheal aspirates of premature infants with respiratory distress syndrome. Pediatric Research 45(4 Part 2): 204A, 1999

Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 88(1): 84-89, 1991

Effect of exogenous surfactant therapy on levels of pulmonary surfactant proteins A and D in preterm infants with respiratory distress syndrome. Journal of Perinatal Medicine 37(5): 561-564, 2009

Surfactant protein a sp a in tracheal fluid tf of infants with respiratory distress syndrome rds and surfactant replacement. Pediatric Research 31(4 Part 2): 317A, 1992

Surfactant phospholipids in trachea-aspirates after treatment of respiratory distress syndrome with surfactant. Pediatric Research 35(4 Part 2): 359A, 1994

Modifications of surfactant phospholipid pattern splp in premature infants with respiratory distress syndrome rds receiving porcine surfactant replacement therapy. Pediatric Research 29(4 Part 2): 319A, 1991

Surfactant inhibitors in amniotic fluid from gastric aspirates in premature infants with respiratory distress syndrome. Biology of the Neonate 76(Suppl. 1): 43-44, 1999

Increase in granulocyte macrophage-colony stimulating factor levels in tracheal lavage samples of infants with Respiratory Distress Syndrome following surfactant therapy. Pediatric Research 47(4 Part 2): 427A, 2000

Does surfactant therapy alter granulocyte macrophage-colony stimulating factor levels in tracheal aspirate samples of infants with respiratory distress syndrome?. Journal of Investigative Medicine 48(1): 25A, 2000

Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS). Intensive Care Medicine 24(5): 494-500, 1998

Surfactant-anti-surfactant immune complexes in infants with respiratory distress syndrome. American Journal of Pathology 122(2): 353-362, 1986

A trial of the use of the Russian surfactant Surfactant HL for treating the respiratory distress syndrome in newborn infants. Anesteziologiia i Reanimatologiia .(4): 36-39, 1998

Surfactant Components and Tracheal Aspirate Inflammatory Markers in Preterm Infants with Respiratory Distress Syndrome. Journal of Pediatrics 203: 442-446, 2018